The company
Artiva Biotherapeutics, Inc.
ARTV · Nasdaq
ARTV stood above a rising 150-day average in 44 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 35.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 5
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $218.4M
- Insider sales, 12 months
- $4.3M
- Officials’ trades on record
- 0
- Institutions holding
- 73 (+34)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Fred AslanChief Executive Officer | sold | 23,463at $7.20 | 6 Oct 2026filed 7 Oct 2026 |
| Fred AslanChief Executive Officer | sold | 61,696at $6.84 | 5 Oct 2026filed 6 Oct 2026 |
| Subhashis BanerjeeChief Medical Officer | sold | 1,099at $6.84 | 5 Oct 2026filed 6 Oct 2026 |
| Jennifer BushCOO, CLO, Compliance Officer | sold | 8,370at $6.84 | 5 Oct 2026filed 6 Oct 2026 |
| Christopher HoranChief Tech Operations Officer | sold | 10,340at $6.84 | 5 Oct 2026filed 6 Oct 2026 |
| Fred AslanChief Executive Officer | sold | 23,429at $10.92 | 8 Sep 2026filed 9 Sep 2026 |
| Fred AslanChief Executive Officer | sold | 61,888at $11.16 | 3 Sep 2026filed 4 Sep 2026 |
| Subhashis BanerjeeChief Medical Officer | sold | 1,100at $11.16 | 3 Sep 2026filed 4 Sep 2026 |
| Jennifer BushCOO, CLO, Compliance Officer | sold | 8,391at $11.16 | 3 Sep 2026filed 4 Sep 2026 |
| Christopher HoranChief Tech Operations Officer | sold | 10,366at $11.16 | 3 Sep 2026filed 4 Sep 2026 |
| Subhashis BanerjeeChief Medical Officer | sold | 8,222at $12.01 | 27 Aug 2026filed 31 Aug 2026 |
| Subhashis BanerjeeChief Medical Officer | sold | 429at $12.00 | 18 Aug 2026filed 19 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P.added · filed 14 Aug 2026 | 17,955,642$174.2M | +8,102,340+82.2% |
| VIKING GLOBAL INVESTORS LPnew · filed 14 Aug 2026 | 2,604,166$25.3M | +2,604,166 |
| Blackstone Inc.new · filed 14 Aug 2026 | 2,403,437$23.3M | +2,403,437 |
| 5AM Venture Management, LLCunchanged · filed 14 Aug 2026 | 2,353,304$22.8M | 00.0% |
| Venrock Adviser, LLCadded · filed 14 Aug 2026 | 2,043,596$19.8M | +434,027+27.0% |
| FRANKLIN RESOURCES INCadded · filed 13 Aug 2026 | 1,997,223$19.4M | +1,476,896+283.8% |
| Caligan Partners LPnew · filed 14 Aug 2026 | 1,736,111$16.8M | +1,736,111 |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 981,815$9.5M | +774,129+372.7% |
| SAMSARA BIOCAPITAL, LLCnew · filed 14 Aug 2026 | 954,861$9.3M | +954,861 |
| Blue Owl Capital Holdings LPnew · filed 11 Aug 2026 | 874,542$8.5M | +874,542 |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.